SecBot SecBot
Biotech Drug Report Generated Oct 31, 2026

Plavix

SNY·Sanofi
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already on market since 1997; generic widely available since 2012.
Why 3/10
Plavix is an approved, marketed drug with no pending regulatory decision, no upcoming PDUFA date, no pivotal readout, and no new indication filing in the next ~12 months. Per the rubric, an approved drug with no imminent new regulatory decision scores 3-5. Plavix is also a very small part of Sanofi's diversified $50B+ revenue base, further limiting any single-drug impact.
Actionable Insight NEUTRAL

There are no hard, dated binary catalysts for Plavix in the next 12 months. The Texas Attorney General lawsuit (filed November 2025) is the most significant active legal overhang, but as a state-level fraud case with no trial date set, it is not a scheduled binary event. Investors should monitor any settlement or court ruling in the Texas case, but Plavix is too small a revenue contributor at Sanofi to drive a material share-price move from legal outcomes alone.

Price Chart

Loading chart...

Executive Summary

Plavix (clopidogrel) is a legacy antiplatelet drug that was first FDA-approved in 1997 and lost US patent exclusivity in 2012. It is now a mature, widely genericized product that generates modest revenue for Sanofi (roughly $1 billion annually versus the company's $50+ billion total). The drug has no pending regulatory catalysts, no upcoming pivotal readouts, and no new indication filings on the horizon. The main investor-relevant developments are ongoing litigation: Texas sued Sanofi and Bristol-Myers Squibb in November 2025 over alleged failure to disclose diminished efficacy in certain populations, while Hawaii settled similar claims for $700 million in May 2025. For a diversified giant like Sanofi, Plavix is a small, declining contributor with no binary catalysts ahead.

How It Works

Plavix is a blood thinner (antiplatelet) that prevents platelets in the blood from sticking together and forming clots. It works by blocking a specific receptor (P2Y12) on platelets, reducing the risk of heart attacks, strokes, and blood clots in patients with cardiovascular disease.

Trial Status

Plavix was FDA-approved on November 17, 1997. US composition-of-matter and market-exclusivity protections expired in 2012, and generic clopidogrel is widely available from multiple manufacturers. The drug remains marketed as a brand in certain international markets.

The Two-Sided Case

▲ Bull Case4
Plavix remains a widely prescribed, standard-of-care antiplatelet therapy with durable demand, generating roughly $1 billion in annual revenue for Sanofi even in a genericized market.
Sanofi and BMS settled Hawaii's decade-long Plavix lawsuit for $700 million in May 2025, removing one major litigation overhang.
The drug's established safety profile and decades of real-world data support continued use in acute coronary syndrome and post-stroke patients worldwide.
Sanofi's overall business is highly diversified (over $50B revenue), so Plavix's gradual decline is easily absorbed and not a material risk to the company.
▼ Bear Case4
US patent exclusivity expired in 2012 and generic clopidogrel is available from at least 15 manufacturers at very low prices, severely limiting brand Plavix revenue in the US market.
Texas Attorney General Ken Paxton sued Sanofi and BMS in November 2025 for allegedly concealing that Plavix is less effective in certain ethnic populations; the case remains ongoing and could result in additional financial penalties.
Individual personal-injury lawsuits over bleeding and TTP (a rare blood disorder) continue to be filed in 2026, creating ongoing legal defense costs and reputational risk.
Newer, more potent antiplatelet agents (e.g., ticagrelor, prasugrel) compete in the P2Y12 inhibitor class, potentially eroding clopidogrel's market share over time.

Upcoming Catalysts

  • No scheduled FDA catalysts, PDUFA dates, or pivotal readouts for Plavix in the next 12 months.
  • Texas Attorney General lawsuit (filed November 2025) is the most significant active legal overhang; any settlement or court ruling would be a watch item.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Sanofi 6-K SNY ·Originating report

Sources · 10

Hover a chip for the title
1 drugpatentwatch.com2 drugs.com3 pharmacompass.com4 settlementinsight.com5 reuters.com6 biospace.com7 news.sanofi.us8 qope.org9 eureka.patsnap.com10 stockanalysis.com